Summary
Sixteen eligible patients with hepatocellular carcinoma, previously untreated, received merbarone 1000 mg/ m2/d for five consecutive days every 21 days. No complete or partial response to treatment was obtained. Seven patients had grade 4 granulocytopenia. One patient died with renal failure. Merbarone in this dose and schedule was ineffective in the treatment of hepatocellular carcinoma.
Similar content being viewed by others
References
Nerenstone SR, Ihde DC, Friedman MA: Clinical trials in primary hepatocellular carcinoma: current status and future directions. Cancer Treat Rev 15(1):1–31, 1988
Davis H, Ramirez G, Ansfield F: Adenocarcinomas of the stomach, pancreas, liver and biliary tract survival of 328 patients treated with fluoropyrimidine therapy. Cancer 33:193, 1994
Sciarrino E, Simonetti R, Moli S, Pagliaro L: Adriamycin treatment for hepatocellular carcinoma. Cancer 56:2751–2755, 1985
Falkson G, Moertel CG, Lavin P, Pretorius FJ, Meds M, Carbone PP: Chemotherapy studies in primary liver cancer. Cancer 42:2149–2156, 1978
Glover A, Chun HG, Kleinman LM, Cooney DA, Plowman J, Grieshaber CK, Malspeis L, Leyland-Jones B: Merbarone: an antitumor agent entering clinical trials. Inv N Drugs 5:137–143, 1987
Drake FH, Hofmann GA, Mong SM, Bartus JO, Hertzberg RP, Johnson RK, Mattern MR, Mirabelli CK:In vitro and intracellular inhibition of topoisomerase II by the antitumor agent merbarone. Cancer Res 49:2578–2583, 1989
DiMaggio JJ, Warrel RP, Muindi J, Stevens YW, Lee SJ, Lowenthal DA, Hanes I, Walsh TD, Baltzer L, Yaldaei S, Young CW: Phase I clinical and pharmacological study of merbarone. Cancer Research 50:1151–1155, 1990
Kraut EH, Grever MR, Staubus AE, Malspeis: Phase I clinical trial of merbarone NSC336628. ASCO abstract A760, 1988
Chang AY, Kim K, Glick J, Anderson T, Karp D, Johnson D: Phase II study of taxol, merbarone and piroxantrone in Stage IV non-small cell lung cancer: The Eastern Cooperative Oncology Group Results. JNCI 85:388–394, 1993
Kraut EH, Fleming T, Macdonald JS, Spiridonidis CH, Bradof JE, Baker LH: Phase II trial of merbarone in pancreatic carcinoma. A Southwest Oncology Group study. Am J Clin Oncol 16:327–328, 1993
Look KY, Blessing JA, Williams L, Morris M: A phase II trial of merbarone (NSC336628) as salvage therapy for squamous cell carcinoma of the cervix: A Gynecologic Oncology Group Study. ASCO abstract A839, 1993
Kraut EH, Bendetti J, Balcerzk SP, Doroshow JH: Phase II trial of merbarone in soft tissue sarcoma. A Southwest Oncology Group study. Inv N Drugs 10:347–349, 1992
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Poplin, E.A., Tangen, C.M., Harvey, W.H. et al. Hepatoma/merbarone. Invest New Drugs 12, 337–340 (1994). https://doi.org/10.1007/BF00873051
Issue Date:
DOI: https://doi.org/10.1007/BF00873051